PortalPublikationenSecond allogeneic transplants for multiple myeloma: a report...

Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party

Standard

Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party. / Hayden, Patrick J; Eikema, Dirk-Jan; de Wreede, Liesbeth C; Koster, Linda; Kröger, Nicolaus; Einsele, Hermann; Minnema, Monique; Dominietto, Alida; Potter, Michael; Passweg, Jacob; Bermúdez, Arancha; Nguyen-Quoc, Stephanie; Platzbecker, Uwe; Tischer, Johanna; Ciceri, Fabio; Veelken, Joan Hendrik; Ljungman, Per; Schaap, Nicolaas; Forcade, Edouard; Carella, Angelo Michele; Gandemer, Virginie; Arcese, William; Bloor, Adrian; Olivieri, Attilio; Vincent, Laure; Beksac, Meral; Schönland, Stefan; Yakoub-Agha, Ibrahim.

in: BONE MARROW TRANSPL, Jahrgang 56, Nr. 10, 10.2021, S. 2367-2381.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Hayden, PJ, Eikema, D-J, de Wreede, LC, Koster, L, Kröger, N, Einsele, H, Minnema, M, Dominietto, A, Potter, M, Passweg, J, Bermúdez, A, Nguyen-Quoc, S, Platzbecker, U, Tischer, J, Ciceri, F, Veelken, JH, Ljungman, P, Schaap, N, Forcade, E, Carella, AM, Gandemer, V, Arcese, W, Bloor, A, Olivieri, A, Vincent, L, Beksac, M, Schönland, S & Yakoub-Agha, I 2021, 'Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party', BONE MARROW TRANSPL, Jg. 56, Nr. 10, S. 2367-2381. https://doi.org/10.1038/s41409-021-01286-x

APA

Hayden, P. J., Eikema, D-J., de Wreede, L. C., Koster, L., Kröger, N., Einsele, H., Minnema, M., Dominietto, A., Potter, M., Passweg, J., Bermúdez, A., Nguyen-Quoc, S., Platzbecker, U., Tischer, J., Ciceri, F., Veelken, J. H., Ljungman, P., Schaap, N., Forcade, E., ... Yakoub-Agha, I. (2021). Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party. BONE MARROW TRANSPL, 56(10), 2367-2381. https://doi.org/10.1038/s41409-021-01286-x

Vancouver

Hayden PJ, Eikema D-J, de Wreede LC, Koster L, Kröger N, Einsele H et al. Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party. BONE MARROW TRANSPL. 2021 Okt;56(10):2367-2381. https://doi.org/10.1038/s41409-021-01286-x

Bibtex

@article{eca46695fa764581b782e26cc063fea6,
title = "Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party",
abstract = "The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) was 38% (30-46%) at 2 years and 25% (17-32%) at 5 years. Patients who had a HLA-identical sibling (HLAid-Sib) donor for their first and second transplants had superior OS (5 year OS: HLAid-Sib/HLAid-Sib: 35% (24-46%); Others 9% (0-17%), p < 0.001). There was a significantly higher incidence of acute grade II-IV GvHD in those patients who had also developed GvHD following their initial HLA-identical sibling allo-HCT (HLAid-Sib/HLAid-Sib: 50% (33-67%); Other 22% (8-36%), p = 0.03). More as opposed to fewer than 2 years between transplants was associated with superior 5-yr OS (31% (21-40%) vs. 10% (1-20%), P = 0.005). On multivariate analysis, consecutive HLA-identical sibling donor transplants conferred a significant OS advantage (0.4 (0.24-0.67), p < 0.001). In the graft failure group, OS was 41% at 2 years. In summary, a second allo-HCT using a HLA-identical sibling donor, if available, provides the best transplant outcomes for relapsed myeloma in this setting.",
author = "Hayden, {Patrick J} and Dirk-Jan Eikema and {de Wreede}, {Liesbeth C} and Linda Koster and Nicolaus Kr{\"o}ger and Hermann Einsele and Monique Minnema and Alida Dominietto and Michael Potter and Jacob Passweg and Arancha Berm{\'u}dez and Stephanie Nguyen-Quoc and Uwe Platzbecker and Johanna Tischer and Fabio Ciceri and Veelken, {Joan Hendrik} and Per Ljungman and Nicolaas Schaap and Edouard Forcade and Carella, {Angelo Michele} and Virginie Gandemer and William Arcese and Adrian Bloor and Attilio Olivieri and Laure Vincent and Meral Beksac and Stefan Sch{\"o}nland and Ibrahim Yakoub-Agha",
year = "2021",
month = oct,
doi = "10.1038/s41409-021-01286-x",
language = "English",
volume = "56",
pages = "2367--2381",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "10",

}

RIS

TY - JOUR

T1 - Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party

AU - Hayden, Patrick J

AU - Eikema, Dirk-Jan

AU - de Wreede, Liesbeth C

AU - Koster, Linda

AU - Kröger, Nicolaus

AU - Einsele, Hermann

AU - Minnema, Monique

AU - Dominietto, Alida

AU - Potter, Michael

AU - Passweg, Jacob

AU - Bermúdez, Arancha

AU - Nguyen-Quoc, Stephanie

AU - Platzbecker, Uwe

AU - Tischer, Johanna

AU - Ciceri, Fabio

AU - Veelken, Joan Hendrik

AU - Ljungman, Per

AU - Schaap, Nicolaas

AU - Forcade, Edouard

AU - Carella, Angelo Michele

AU - Gandemer, Virginie

AU - Arcese, William

AU - Bloor, Adrian

AU - Olivieri, Attilio

AU - Vincent, Laure

AU - Beksac, Meral

AU - Schönland, Stefan

AU - Yakoub-Agha, Ibrahim

PY - 2021/10

Y1 - 2021/10

N2 - The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) was 38% (30-46%) at 2 years and 25% (17-32%) at 5 years. Patients who had a HLA-identical sibling (HLAid-Sib) donor for their first and second transplants had superior OS (5 year OS: HLAid-Sib/HLAid-Sib: 35% (24-46%); Others 9% (0-17%), p < 0.001). There was a significantly higher incidence of acute grade II-IV GvHD in those patients who had also developed GvHD following their initial HLA-identical sibling allo-HCT (HLAid-Sib/HLAid-Sib: 50% (33-67%); Other 22% (8-36%), p = 0.03). More as opposed to fewer than 2 years between transplants was associated with superior 5-yr OS (31% (21-40%) vs. 10% (1-20%), P = 0.005). On multivariate analysis, consecutive HLA-identical sibling donor transplants conferred a significant OS advantage (0.4 (0.24-0.67), p < 0.001). In the graft failure group, OS was 41% at 2 years. In summary, a second allo-HCT using a HLA-identical sibling donor, if available, provides the best transplant outcomes for relapsed myeloma in this setting.

AB - The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) was 38% (30-46%) at 2 years and 25% (17-32%) at 5 years. Patients who had a HLA-identical sibling (HLAid-Sib) donor for their first and second transplants had superior OS (5 year OS: HLAid-Sib/HLAid-Sib: 35% (24-46%); Others 9% (0-17%), p < 0.001). There was a significantly higher incidence of acute grade II-IV GvHD in those patients who had also developed GvHD following their initial HLA-identical sibling allo-HCT (HLAid-Sib/HLAid-Sib: 50% (33-67%); Other 22% (8-36%), p = 0.03). More as opposed to fewer than 2 years between transplants was associated with superior 5-yr OS (31% (21-40%) vs. 10% (1-20%), P = 0.005). On multivariate analysis, consecutive HLA-identical sibling donor transplants conferred a significant OS advantage (0.4 (0.24-0.67), p < 0.001). In the graft failure group, OS was 41% at 2 years. In summary, a second allo-HCT using a HLA-identical sibling donor, if available, provides the best transplant outcomes for relapsed myeloma in this setting.

U2 - 10.1038/s41409-021-01286-x

DO - 10.1038/s41409-021-01286-x

M3 - SCORING: Journal article

C2 - 33976382

VL - 56

SP - 2367

EP - 2381

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 10

ER -